Is a daily dose of 60 µg vitamin K2 (menaquinone‑7) safe for an elderly patient with chronic kidney disease stage 3b‑4?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Vitamin K2 (60 µg MK-7) is Safe for Elderly CKD Stage 3b-4 Patients

Yes, 60 µg daily of vitamin K2 (menaquinone-7) is safe for an elderly patient with CKD stage 3b-4, provided they are not taking warfarin or other vitamin K antagonist anticoagulants.

Key Safety Considerations

Anticoagulant Use is the Primary Contraindication

The 2020 KDOQI nutrition guideline explicitly states that patients receiving anticoagulant medicines that inhibit vitamin K activity (e.g., warfarin) should not receive vitamin K supplements 1. This is the only absolute contraindication mentioned in current guidelines.

  • If your patient is on warfarin → Do not give vitamin K2
  • If on DOACs (apixaban, rivaroxaban, etc.) → Safe to proceed (these do not interact with vitamin K)
  • If on no anticoagulants → Safe to proceed

Safety Evidence in CKD Populations

The dose you're asking about (60 µg) is well below the doses studied in CKD patients:

  • The K4Kidneys trial used 400 µg daily of MK-7 in CKD stage 3b-4 patients for 12 months with no safety concerns 2
  • A recent dialysis study used 360 µg daily for 52 weeks and found no detectable coagulation activation, no increase in vascular events, and no difference in serious adverse events compared to placebo 3
  • The 2025 KDIGO guideline review references multiple trials using 360-400 µg MK-7 in CKD patients without safety issues 4

Your proposed 60 µg dose is approximately 6-fold lower than these well-tolerated doses.

General Safety Profile

A comprehensive US Pharmacopeial Convention safety review concluded that menaquinone-7 as a dietary supplement is not associated with any serious risk to health 5. The typical supplemental doses range from 45-360 µg daily, and your 60 µg dose falls at the lower end of this spectrum.

Efficacy Considerations (Though Not Your Primary Question)

While safety is established, it's worth noting that efficacy data are mixed:

  • The K4Kidneys trial (400 µg MK-7 in CKD 3b-4) showed no benefit for vascular stiffness or calcification progression 2
  • However, a 2026 trial in coronary artery disease patients found that 360 µg MK-7 significantly slowed calcification progression over 2 years 6
  • Studies consistently show MK-7 supplementation improves vitamin K status biomarkers (reduces dp-ucMGP and PIVKA-II) even if clinical outcomes remain uncertain 7, 8, 9

Practical Recommendation

Proceed with 60 µg daily MK-7 supplementation if:

  • Patient is NOT on warfarin
  • You document baseline vitamin K status if possible (though not required)
  • You monitor for any unexpected bleeding (theoretical concern, though not observed in trials)

Do not supplement if:

  • Patient is on warfarin or other vitamin K antagonists 1

The dose is conservative, well within established safety margins, and poses minimal risk in this population based on current evidence.

Related Questions

What is the optimal daily dose of vitamin K2 (menaquinone‑7) for a typical adult without a specific medical condition?
What are the indications and evidence supporting vitamin K2 (menaquinone‑7) supplementation?
Can a patient with chronic kidney disease (CKD) stage 3a take vitamin K2 (Menatetrenone (MK7)) alone or in combination with other vitamins?
Does vitamin D3 (D3) and vitamin K2 (K2) supplementation increase potassium levels, particularly in patients with pre-existing kidney disease or those taking medications such as Angiotensin-Converting Enzyme inhibitors (ACE inhibitors) or potassium-sparing diuretics?
Is combined vitamin D3 and vitamin K2 (menaquinone‑7) supplementation safe for breastfeeding women?
Is it safe long-term for an elderly patient in his late 80s with chronic kidney disease stage 3b–4 to take 4,500 IU of vitamin D3 (cholecalciferol) on one day and about 1,700 IU on the next (from diet and supplements)?
In Pediatric Advanced Life Support (PALS), what is the most common cause of cardiac arrest in infants and children?
What isolation precautions should be implemented in skilled nursing facilities for residents with transmissible infections?
How should hypothyroidism be treated in an elderly female patient in her late 80s presenting with malaise, fatigue, elevated thyroid-stimulating hormone and normal free thyroxine?
Is amoxicillin 875 mg appropriate for a breastfeeding mother with a 4‑day‑old infant?
Is a total daily magnesium intake of 300 mg (diet plus supplement) safe for a patient aged ≥80 years with chronic kidney disease stage 3b–4 for long‑term use?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.